This review assessed the effectiveness of lipid-lowering therapies in reducing the incidence of stroke. The authors concluded that such treatments do reduce stroke incidence in patients with a history of heart disease. This review involved a large number of patients and the conclusions are likely to be broadly accurate.
reduction during the study between the treated and control groups. Relative risks (RRs) were calculated for each outcome for each trial.
Methods of synthesis
How were the studies combined? The trials were combined in a fixed-effect meta-analysis. A pooled estimate of overall RR was calculated using the inverse variance. An effect model analysis, using a weighted regression model, was also performed. A weighted linear regression model was used to assess the relationship between cholesterol reduction and reduction in stroke incidence.
How were differences between studies investigated?
A chi-squared test for heterogeneity was carried out on the overall pooled analysis. Subgroups were identified on the basis of treatment type, and chi-squared tests for heterogeneity were also conducted for each subgroup.
Results of the review
Thirty-eight RCTs with 83,161 patients were included in the review. Ten trials were of primary prevention and 28 were of secondary coronary prevention.
The pooled estimate of the 31 trials (n=70,396) included in themeta-analysis showed that stroke incidence in the lipidlowering therapy groups was lower than in the placebo groups (RR 0.828, P<0.001). No statistically significant heterogeneity was found between the trials or between the types of treatment.
There was no difference between the lipid-lowering therapy andplacebo groups in the incidence of fatal strokes (RR 1.09, 95% CI confidence interval: 0.86, 1.38).
Ten trials (n=30,766) reported the incidence of haemorrhagicstroke. There was no significant difference between the groups (RR 1.16, 95% CI: 0.75, 1.80).
Eight of the 10 primary prevention trials were included in themeta-analysis (n=28,553). Stroke incidence was not significantly different in the two groups (RR 0.95, P=0.67).
Twenty-three of the 28 secondary prevention trials were includedin the meta-analysis (n=41,843). Stroke incidence in the lipid-lowering therapy groups was lower than in the placebo groups (RR 0.74, 95% CI: 0.64, 0.86).
Statin treatment reduced stroke incidence by the greatest amountin comparison with placebo (RR 0.76, 95% CI: 0.66, 0.87) .
The pooled estimate showed that the incidence of myocardialinfarction was significantly lower in lipid-lowering therapy groups than in placebo groups: (RR reduction 22%, P<0.001).
The weighted regression showed a significant correlation betweenthe reduction in RR of stroke and total cholesterol levels. The final cholesterol levels showed a clear separation between benefit and no benefit of lipid-lowering therapy on stroke incidence, with a cut-off for benefit of 232 mg/dL.
